Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
MDxHealth sees FY23 revenue $65M-$70M, consensus $67.03M » 16:27
11/29/22
11/29
16:27
11/29/22
16:27
MDXH

MDxHealth

$7.20 /

-0.61 (-7.81%)

"Further, we are…

"Further, we are also pleased to note the expanded indication for our GPS test in the recently updated NCCN Prostate Cancer guidelines", continued McGarrity. "The addition of GPS to our current menu of tests targeted into urology and prostate cancer reflects our strategy to generate sustainable growth and enable mdxhealth to become the leading precision diagnostics company with the most comprehensive test menu focused on prostate cancer. While early, we are well into our integration plan for our GPS test and have our expanded field sales organization in place to support continued growth. With multiple levers for sustainable revenue growth, the company is initiating 2023 revenue guidance of $65-70 million."

ShowHide Related Items >><<
MDXH MDxHealth
$7.20 /

-0.61 (-7.81%)

MDXH MDxHealth
$7.20 /

-0.61 (-7.81%)

08/26/22 BTIG
MDxHealth price target raised to $15 from $13 at BTIG
07/18/22 Oppenheimer
MDxHealth assumed with an Outperform at Oppenheimer
MDXH MDxHealth
$7.20 /

-0.61 (-7.81%)

Earnings
MDxHealth cuts FY22 revenue view to $36.5M-$37.5M from $40M-$42M » 16:26
11/29/22
11/29
16:26
11/29/22
16:26
MDXH

MDxHealth

$7.20 /

-0.61 (-7.81%)

Consensus $40.53M.…

Consensus $40.53M. Michael McGarrity, CEO of mdxhealth, commented: "Securing Medicare reimbursement for new molecular diagnostic technologies is now a more rigorous and iterative process under the new Foundational LCD program. Due to the additional time required to obtain Medicare coverage, the Company no longer expects to receive Medicare payments for Select mdx tests in 2022. Based on this development, coupled with revenue cycle timing associated with the acquisition and integration of the GPS test, the Company is revising its 2022 revenue guidance to $36.5-37.5 million from $40-42 million. We remain confident in our ability to address any remaining questions with MolDX, which we believe will lead to a positive reimbursement decision for Select mdx in the first half of 2023. To further underscore the growing diagnostic value of Select mdx, we are also pleased to report that the results of an independent, multi-institutional clinical study was recently recognized as a best poster by the American Urological Association, demonstrating the diagnostic accuracy of Select mdx and as well as its complementary utility with mpMRI for the prediction of prostate cancer in biopsies."

ShowHide Related Items >><<
MDXH MDxHealth
$7.20 /

-0.61 (-7.81%)

MDXH MDxHealth
$7.20 /

-0.61 (-7.81%)

08/26/22 BTIG
MDxHealth price target raised to $15 from $13 at BTIG
07/18/22 Oppenheimer
MDxHealth assumed with an Outperform at Oppenheimer
MDXH MDxHealth
$7.20 /

-0.61 (-7.81%)

Hot Stocks
MDxHealth provides business update » 16:24
11/29/22
11/29
16:24
11/29/22
16:24
MDXH

MDxHealth

$7.20 /

-0.61 (-7.81%)

MDxHealth provided…

MDxHealth provided clinical and reimbursement product developments, updated guidance for FY22, and initial guidance for 2023. Under the foundational LCD process recently implemented by the Molecular Diagnostics Services Program administered by Palmetto GBA, all tests within an LCD-covered indication must submit a Technical Assessment for review and consideration. The indication for use of Select mdx is covered by Medicare's foundational LCD Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer, which became effective in July. The Select mdx TA has already been submitted and we are engaged in an interactive review process with MolDX. Based on the company's most recent communication with MolDX, a final coverage decision is not expected until H1 2023. The recently released NCCN for Prostate Cancer Guideline expands the indication for use of the GPS test to include high-risk patients with localized prostate cancer. In August, mdxhealth announced that it acquired the Oncotype DX Genomic Prostate Score test from Exact Sciences, further solidifying the company's leadership in the precision diagnostics urology market. This expanded criteria to address high-risk patients provides additional validation for the clinical utility of GPS in making prostate cancer treatment decisions and enables the company to more fully serve its targeted patient population.

ShowHide Related Items >><<
MDXH MDxHealth
$7.20 /

-0.61 (-7.81%)

MDXH MDxHealth
$7.20 /

-0.61 (-7.81%)

08/26/22 BTIG
MDxHealth price target raised to $15 from $13 at BTIG
07/18/22 Oppenheimer
MDxHealth assumed with an Outperform at Oppenheimer
MDXH MDxHealth
$7.20 /

-0.61 (-7.81%)

Over a month ago
Earnings
MDxHealth reports Q3 revenue $11.2M » 16:12
10/27/22
10/27
16:12
10/27/22
16:12
MDXH

MDxHealth

$6.55 /

+0.24 (+3.80%)

Q3-2022 revenue of…

Q3-2022 revenue of $11.2M, representing an increase of 103% over Q3-2021; excluding revenues from the recently acquired Oncotype DX Genomic Prostate Score test, Q3-2022 revenue increased 42% over Q3-2021, reflecting continued execution by our sales team, expanded coverage of our menu and efficient revenue cycle management; Closed our acquisition of the Oncotype DX GPS business from Exact Sciences on August 2 Continued commercial uptake of our Urinary Tract Infection test, newly branded as Resolve mdx

ShowHide Related Items >><<
MDXH MDxHealth
$6.55 /

+0.24 (+3.80%)

MDXH MDxHealth
$6.55 /

+0.24 (+3.80%)

08/26/22 BTIG
MDxHealth price target raised to $15 from $13 at BTIG
07/18/22 Oppenheimer
MDxHealth assumed with an Outperform at Oppenheimer
11/29/21 Oppenheimer
MDxHealth initiated with an Outperform at Oppenheimer
11/29/21 BTIG
MDxHealth initiated with a Buy at BTIG
MDXH MDxHealth
$6.55 /

+0.24 (+3.80%)

  • 04
    Nov
Conference/Events
MDxHealth management to meet virtually with BTIG » 04:55
10/12/22
10/12
04:55
10/12/22
04:55
MDXH

MDxHealth

$6.70 /

+ (+0.00%)

Life Science and…

Life Science and Diagnostic Tools Analyst Massaro holds a virtual meeting with management on October 12 hosted by BTIG.

ShowHide Related Items >><<
MDXH MDxHealth
$6.70 /

+ (+0.00%)

MDXH MDxHealth
$6.70 /

+ (+0.00%)

08/26/22 BTIG
MDxHealth price target raised to $15 from $13 at BTIG
07/18/22 Oppenheimer
MDxHealth assumed with an Outperform at Oppenheimer
11/29/21 Oppenheimer
MDxHealth initiated with an Outperform at Oppenheimer
11/29/21 BTIG
MDxHealth initiated with a Buy at BTIG
MDXH MDxHealth
$6.70 /

+ (+0.00%)

  • 04
    Nov
Conference/Events
MDxHealth management to meet with BTIG » 04:55
10/11/22
10/11
04:55
10/11/22
04:55
MDXH

MDxHealth

$6.70 /

+0.11 (+1.67%)

Life Science and…

Life Science and Diagnostic Tools Analyst Massaro holds a meeting with management in Minneapolis on October 11 hosted by BTIG.

ShowHide Related Items >><<
MDXH MDxHealth
$6.70 /

+0.11 (+1.67%)

MDXH MDxHealth
$6.70 /

+0.11 (+1.67%)

08/26/22 BTIG
MDxHealth price target raised to $15 from $13 at BTIG
07/18/22 Oppenheimer
MDxHealth assumed with an Outperform at Oppenheimer
11/29/21 Oppenheimer
MDxHealth initiated with an Outperform at Oppenheimer
11/29/21 BTIG
MDxHealth initiated with a Buy at BTIG
MDXH MDxHealth
$6.70 /

+0.11 (+1.67%)

  • 04
    Nov
Conference/Events
MDxHealth management to meet virtually with BTIG » 13:28
10/10/22
10/10
13:28
10/10/22
13:28
MDXH

MDxHealth

$6.70 /

+0.11 (+1.67%)

Life Science and…

Life Science and Diagnostic Tools Analyst Massaro holds a virtual meeting with management on October 12 hosted by BTIG.

ShowHide Related Items >><<
MDXH MDxHealth
$6.70 /

+0.11 (+1.67%)

MDXH MDxHealth
$6.70 /

+0.11 (+1.67%)

08/26/22 BTIG
MDxHealth price target raised to $15 from $13 at BTIG
07/18/22 Oppenheimer
MDxHealth assumed with an Outperform at Oppenheimer
11/29/21 Oppenheimer
MDxHealth initiated with an Outperform at Oppenheimer
11/29/21 BTIG
MDxHealth initiated with a Buy at BTIG
MDXH MDxHealth
$6.70 /

+0.11 (+1.67%)

  • 04
    Nov
Conference/Events
MDxHealth management to meet with BTIG » 13:27
10/10/22
10/10
13:27
10/10/22
13:27
MDXH

MDxHealth

$6.70 /

+0.11 (+1.67%)

Life Science and…

Life Science and Diagnostic Tools Analyst Massaro holds a meeting with management in Minneapolis on October 11 hosted by BTIG.

ShowHide Related Items >><<
MDXH MDxHealth
$6.70 /

+0.11 (+1.67%)

MDXH MDxHealth
$6.70 /

+0.11 (+1.67%)

08/26/22 BTIG
MDxHealth price target raised to $15 from $13 at BTIG
07/18/22 Oppenheimer
MDxHealth assumed with an Outperform at Oppenheimer
11/29/21 Oppenheimer
MDxHealth initiated with an Outperform at Oppenheimer
11/29/21 BTIG
MDxHealth initiated with a Buy at BTIG
MDXH MDxHealth
$6.70 /

+0.11 (+1.67%)

  • 04
    Nov
Conference/Events
MDxHealth management to meet with Piper Sandler » 04:55
09/27/22
09/27
04:55
09/27/22
04:55
MDXH

MDxHealth

$6.69 /

+ (+0.00%)

Meeting to be held in New…

Meeting to be held in New York on September 27 hosted by Piper Sandler.

ShowHide Related Items >><<
MDXH MDxHealth
$6.69 /

+ (+0.00%)

MDXH MDxHealth
$6.69 /

+ (+0.00%)

08/26/22 BTIG
MDxHealth price target raised to $15 from $13 at BTIG
07/18/22 Oppenheimer
MDxHealth assumed with an Outperform at Oppenheimer
11/29/21 Oppenheimer
MDxHealth initiated with an Outperform at Oppenheimer
11/29/21 BTIG
MDxHealth initiated with a Buy at BTIG
MDXH MDxHealth
$6.69 /

+ (+0.00%)

  • 04
    Nov
Conference/Events
MDxHealth management to meet with Piper Sandler » 16:06
09/19/22
09/19
16:06
09/19/22
16:06
MDXH

MDxHealth

$7.20 /

-0.03 (-0.41%)

Meeting to be held in New…

Meeting to be held in New York on September 27 hosted by Piper Sandler.

ShowHide Related Items >><<
MDXH MDxHealth
$7.20 /

-0.03 (-0.41%)

MDXH MDxHealth
$7.20 /

-0.03 (-0.41%)

08/26/22 BTIG
MDxHealth price target raised to $15 from $13 at BTIG
07/18/22 Oppenheimer
MDxHealth assumed with an Outperform at Oppenheimer
11/29/21 Oppenheimer
MDxHealth initiated with an Outperform at Oppenheimer
11/29/21 BTIG
MDxHealth initiated with a Buy at BTIG
MDXH MDxHealth
$7.20 /

-0.03 (-0.41%)

  • 04
    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.